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Abstract
Background:  Severe hypertriglyceridaemia due to chylomicronemia may trigger an acute
pancreatitis. However, the basic underlying mechanism is usually not well understood. We decided
to analyze some proteins involved in the catabolism of triglyceride-rich lipoproteins in patients with
severe hypertriglyceridaemia.
Methods:  Twenty-four survivors of acute hypertriglyceridaemic pancreatitis (cases) and 31
patients with severe hypertriglyceridaemia (controls) were included. Clinical and anthropometrical
data, chylomicronaemia, lipoprotein profile, postheparin lipoprotein lipase mass and activity,
hepatic lipase activity, apolipoprotein C II and CIII mass, apo E and A5 polymorphisms were
assessed.
Results: Only five cases were found to have LPL mass and activity deficiency, all of them thin and
having the first episode in childhood. No cases had apolipoprotein CII deficiency. No significant
differences were found between the non-deficient LPL cases and the controls in terms of obesity,
diabetes, alcohol consumption, drug therapy, gender distribution, evidence of fasting
chylomicronaemia, lipid levels, LPL activity and mass, hepatic lipase activity, CII and CIII mass or
apo E polymorphisms. However, the SNP S19W of apo A5 tended to be more prevalent in cases
than controls (40% vs. 23%, NS).
Conclusion: Primary defects in LPL and C-II are rare in survivors of acute hypertriglyceridaemic
pancreatitis; lipase activity measurements should be restricted to those having their first episode
during chilhood.
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Background
Among patients with acute pancreatitis, 1.3 to 3.5% are
due to hypertriglyceridaemia, also known as hypertriglyc-
eridaemic pancreatitis [1,2], some times relapsing and
being even more severe than lithiasic acute pancreatitis
[3]. Acute hypertriglyceridaemic pancreatitis forms part of
the Chylomicronaemia Syndrome, defined as the pres-
ence of one or more of the typical signs (eruptive xantho-
mas, lipidaemia retinalis, recurrent abdominal pain or
acute pancreatitis) in a patient with plasma triglyceride
concentrations >22.58 mmol/L[4].
Genetic causes of the syndrome are rare and include defi-
ciency of lipoprotein lipase (LPL), apolipoprotein C-II,
and familial inhibitor of LPL. Other genes are also
involved in the catabolism of chylomicrons, such as those
for apolipoprotein E, apolipoprotein A-V [5] and glycosyl-
phosphatidylinositol hgih density lipoprotein-binding
protein [6,7] Patients with familial forms of hypertriglyc-
eridaemia in combination with secondary acquired disor-
ders (obesity, diabetes, pregnancy or drugs, including
estrogens, retinoids, highly-active antiretroviral drugs)
account for most individuals presenting with chylomicro-
naemia [8].
Although the presence of chylomicrons is necessary for
the development of hypertriglyceridaemic pancreatitis
and these are considered to be present when the triglycer-
ides >11.29 mmol/L, it is common in out-patient clinics
to see patients with much higher concentrations who are
nevertheless asymptomatic and have not required admis-
sion for hypertriglyceridaemic pancreatitis. Few studies on
the catabolism of triglyceride-rich lipoproteins have been
published [9], with most reports concerning isolated cases
with severe chylomicronaemia triggered by drugs or preg-
nancy [10-17]. Furthermore, additional interest concerns
the identification of LPL-deficient patients for the poten-
tial use of intramuscular administration of an adeno-asso-
ciated virus serotype 1 (AAV1) vector encoding the human
LPL(S447X) variant cDNA (AAV1-LPL(S447X)), which
normalized the chylomicronaemia in LPL-/- mice for
more than 1 year [18] and is providing new data on
humans[19].
We therefore studied LPL mass and activity, hepatic lipase
activity, the levels of apolipoprotein C-II and apo E and
apo A-V polymorphisms in order to detect any differences
between persons with hypertriglyceridaemia who devel-
oped hypertriglyceridaemic pancreatitis and those who
did not.
Methods
Patient selection
We studied 24 patients who were referred to our Lipids
Unit after having hypertriglyceridaemic pancreatitis (HP
Group). To be included in this group the patients had to
have suffered at least one episode of acute pancreatitis
(symptoms compatible with raised amylases in blood and
urine and/or lipase in blood and morphological involve-
ment of the pancreas on abdominal CT) and triglyceride
concentrations on admission >11.29 mmol/L or, failing
this, a lipaemic serum. All the patients with hypertriglyc-
eridaemic pancreatitis were studied from several weeks to
months after the episode of acute pancreatitis, when they
were at home and with no symptoms.
In order to compare the different variables, a control
group was recruited consisting of 31 patients referred to
our Lipids Unit with severe hypertriglyceridaemia (triglyc-
erides >11.29 mmol/L on at least one occasion), which
thus represented a risk of having had hypertriglyceridae-
mic pancreatitis (HTG Group). As our centre has no pae-
diatric unit, all the participants were older than 14 years
of age.
All the patients and controls were being treated with diet
and/or lipid lowering drugs. Due to ethical reasons, in no
case was the medication stopped or changed because of
inclusion in the study.
The clinical records of all the patients with hypertriglycer-
idaemic pancreatitis were reviewed retrospectively, in
order to identify any factors predisposing to chylomicro-
naemia that could have led to the development of acute
pancreatitis. Data were recorded on alcohol consumption,
the presence of diabetes mellitus and its degree of control,
dietary transgressions, pregnancy, and the intake of oes-
trogens or other drugs that could potentially increase trig-
lyceride concentrations in predisposed patients (retinoic
acid, antiretroviral therapy, corticoids, etc...). We consid-
ered moderate alcohol consumption less than 40 g in men
and 20 g in women. No patients with alcoholic pancreati-
tis were included in our series. Previous diagnosis of co-
morbidities, such as hypertension, vascular disease, fatty
liver and coronary heart disease were also recorded.
Because few relatives were available for lipid analyses,
family history of hyperlipidemia relied mainly in patient's
recall.
The study was approved by the Research and Ethics Com-
mittee of Virgen de la Victoria Hospital and all the
patients gave written informed consent.
Lipid and Lipoprotein Profile
Venous blood samples were obtained from each subject
after a 12-hour fast. The baseline sample was used for
lipid analysis, lipoprotein and apolipoprotein fractions
and the second sample (drawn from the contralateral arm
15 minutes after administering sodium heparin (100 IU/BMC Gastroenterology 2009, 9:46 http://www.biomedcentral.com/1471-230X/9/46
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kg) was used to measure the LPL lipase and hepatic lipase
activity and the LPL mass.
The lipoproteins were separated by ultracentrifugation
and later precipitation [20]. The separation of the chylom-
icrons in each sample was done by ultracentrifugation for
30 minutes at 105,000 × g. Because our technique is not
able to distinguish between smaller chylomicrons and
larger VLDL the lipoprotein obtained were chylomicron-
like particles. After chylomicrons-like particles were
removed, plasma was ultracentrifugated for 18 hours,
10°C, d 1.006 Kg/L at 105,000 × g, in order to separate
VLDL. The infranatant fraction, containing LDL plus HDL,
was reconstituted to the original volume and HDL was
measured after precipitation of LDL [20]. Cholesterol and
triglycerides were measured in plasma and in each lipo-
protein fraction by commercial enzymatic methods (ABX,
Montpelier, France). The plasma apolipoproteins (A-I, B-
100, C-II, C-III, E] were quantified by commercial immu-
noturbidimetric methods (ABX, and DAIICHI, Tokyo,
Japan). These measurements were all done at the Centro
de Investigaciones Médico-Sanitarias (CIMES) of Malaga
University, Spain.
Lipoprotein Activity and Mass
The LPL activity assay was done on an Intralipid 10%
emulsion and the hepatic lipase activity was measured
using a gum Arabic-stabilized emulsion of triolein as pre-
viously published [21,22]. Each sample for LPL and
hepatic lipase activities was assayed in triplicate and two
standard samples were analysed in each assay. The activi-
ties of LPL and hepatic lipase are shown as mU/mL of
plasma. One mU corresponds to nmol of fatty acid
released per minute at 25° [23].
The LPL mass was measured by ELISA (19), using purified
chicken antibodies to coat the wells and the monoclonal
antibody 5D2, both against bovine LPL (Courtesy of Dr J.
Brunzell, Seattle, USA). The mean values of all the sam-
ples were calculated for at least 3 different dilutions. The
results are expressed in ng/mL. Purified bovine milk LPL
was used as an assay standard.
Postheparin values from 20 healthy subjects were: LPL
activity 56 ± 23 mU/mL (range 17–92) and LPL mass 254
± 108 ng/mL (range 117–419).
Polymorphisms of Apolipoproteins E and A-V
Genomic DNA was extracted by BioRobot® EZ1 (QIA-
GEN). Genotyping for Apo E and APO A5 polymorphisms
was carried out by PCR and restriction fragment analysis.
Amplification reactions were performed in an iCycler iQ™
(BioRad) thermal cycler employing iQ™ Supermix (Bio-
Rad) as reaction mix. The primers and thermal protocols
used were as previously described [24,25], with minor
modifications.
Statistical Analysis
Comparison of the quantitative variables between groups
was done with the Student t test for independent data and
analysis of variance (ANOVA), or the Mann-Whitney "U"
test and the Kruskal-Wallis "H" test if the variables failed
to adjust to normality. Analysis of the association of qual-
itative characteristics was done with the χ-square test or
Fisher's exact test if the expected frequency was less than
5. All the tests were bilateral and the results considered
significant if the p < 0.05. The database and the various
tests mentioned were done with the programme SPSS
12.0 (SPSS Inc, Chicago, USA).
Results
The 24 patients with hypertriglyceridaemic pancreatitis
were mostly men and smokers, with a family history of
dyslipidaemia, and half of them were moderate consum-
ers of alcohol. The only difference between the two groups
was a lower prevalence of overweight or obesity in the
patients with hypertriglyceridaemic pancreatitis. About
half of patients in each group were treated with fibrates.
(Table 1).
Over half the patients with hypertriglyceridaemic pancre-
atitis had consumed alcohol prior to the episode, four
patients (20%) had diabetes mellitus which was to some
degree poorly controlled, and one patient had just started
steroid therapy for Evans Syndrome. No triggering factor
was found in four patients. None of the patients with
hypertriglyceridaemic pancreatitis was pregnant or had
consumed estrogens. A positive family history of hyperli-
pidaemia was around 50% in both groups, but probably
it was underestimated because many relatives could not
be analyzed.
The group with hypertriglyceridaemic pancreatitis showed
a non-significant tendency to have higher levels of triglyc-
erides and cholesterol in the chylomicron-like fraction
and a higher CIII/CII ratio. Fasting chylomicrons were
present in 12/24 (50%) of the group with hypertriglyceri-
daemic pancreatitis (HP) and in 20/31 (64%) of the con-
trol HTG group without pancreatitis. Chylomicrons were
even present in 12 patients whose fasting triglyceride con-
centrations were below 5.65 mmol/L (Figure 1). No
patient was found to have a deficit of apolipoprotein C-II
(Table 2).
The patients with hypertriglyceridaemic pancreatitis had a
lower post-heparin LPL mass and activity than the control
group, but no differences were found in hepatic lipase
activity, as expected (Table 2). Individual analysis of the
post-heparin LPL activity (Figure 2) showed five personsBMC Gastroenterology 2009, 9:46 http://www.biomedcentral.com/1471-230X/9/46
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whose LPL mass and activity was almost null. Four of
these five patients with a deficiency came from the hyper-
triglyceridaemic pancreatitis group and one from the HTG
group. The latter was the sister of a patient with a defi-
ciency. Although she had never been admitted with acute
pancreatitis she had suffered recurrent episodes of
abdominal pain since she was a child. Accordingly, we
decided to divide the group of hypertriglyceridaemic pan-
creatitis patients into two subgroups, one with a defi-
ciency (HPD) and the other with no deficiency (HPND).
Table 3 clearly shows that the HPD patients were younger,
had their first episode of hypertriglyceridaemic pancreati-
tis at an earlier age and a more recurrent course; they
showed lower body-mass index than the patients with
HPND and the HTG group. Moreover, the five patients
with HPD had significantly higher levels of triglycerides,
lipids in the fraction of chylomicrons-like and serum apo
E, whereas they had significantly lower levels of LDL cho-
lesterol and HDL cholesterol, as well as the serum concen-
tration of apolipoproteins B-100 and A-1 (Table 4).
(Table 4). By contrast, no differences were found in lipids,
lipoproteins, apolipoproteins or post-heparin lipase mass
or activity between the HTG and the HPND groups (Table
4). Indeed, no differences were found between the groups
for apo E polymorphisms; although the rare S19W allele
of the apolipoprotein A-V gene was non-significantly
more frequent in the HPND (40%) patients than the HTG
group (23%).
Discussion
Our study focussed on the analysis of post-heparin lipo-
protein-lipase activity and the level of apolipoprotein C-II
in persons who had survived at least one episode of hyper-
triglyceridaemic pancreatitis in comparison with persons
who were at risk for the same disorder due to having
severe hypertriglyceridaemia with triglycerides >10
mmol/L [26]. The study led to the identification of five
persons with a deficiency in LPL mass and activity, no case
with a deficiency of apolipoprotein C-II and a borderline
increase in apo A V S19W polymorphism in HP group.
Our findings are coherent with previous reports, in which
the vast majority of cases with severe hypertriglyceridae-
mia (phenotype I or V) are due to the presence of one or
more secondary causes. For example, just five of 123
patients with severe hypertriglyceridaemia (triglycer-
ides>22.58 mmol/L) were deficient in LPL [27,28]. Addi-
tionally, no case of LPL deficiency was reported among 27
adults with hypertriglyceridaemic pancreatitis [29]. More-
Table 1: Clinical and demographic data
HP
N = 24
HTG
N = 31
p
Age (years) 43 ± 11 46 ± 9 NS
Age first onset AP 40 ± 11 -
AP Episo N° 2.3 ± 1.9 (1–9)
1epis 9 (37.5%)
2epis 9 (37.5%)
≥ 3 epis 6 (25%)
Sex (Men) 21 (90%) 28 (87%) NS
Smokers 15 (62%) 19 (61%) NS
Alcohol users 12 (50%) 17 (55%) NS
AF 13 (54%) 13 (42%) NS
BMI (kg/m2) 26.5 ± 4.0 29.3 ± 5.0 0.03
<25 10 (42%) 4(13%)
25–30 10 (42%) 14 (45%)
>30 4 (17%) 13 (42%)
Diet only 11 (45%) 8 (26%)
Fibrates 13 (54%) 18 (58%)
Niacin 1 (4%) 0 NS
Fish oils 0 5 (16%)
Statins 1 (4%) 4 (13%)
Comorbidities
Diabetes 7 (29) 9 (29) NS
Hypertension 5 (21) 13 (42) 0.052
Fatty Liver 5 (21) 9 (29) NS
Vascular disease 3 (12) 5 (16) NS
Coronary artery disease 1 (4) 5 (16) NS
AP: acute pancreatitis. AF: positive family history.
HP : hypertriglyceridaemic pancreatitis; HTG: severe 
hypertriglyceridaemia;
Chylomicron-like triglycerides as a fraction of total plasma  triglycerides Figure 1
Chylomicron-like triglycerides as a fraction of total 
plasma triglycerides.B
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Table 2: Serum lipids, lipoproteins, apolipoproteins and LPL mass and LPL and HL activities in postheparin and preheparin plasma samples
HP
N = 24
HTG
N = 31
p
Total cholesterol 6.96 ± 3.72 6.56 ± 1.68 NS
TG 3.53 (2.07–8.75) 4.87 (2.70–8.41) NS
VLDL-Chol 0.83 ± 0.44 0.91 ± 0.47 NS
HDL-Chol 0.91 ± 0.49 0.88 ± 0.39 NS
LDL-Chol 2.95 ± 1.47 3.28 ± 1.40 NS
VLDL-TG 1.39 (1.06–1.97) 1.41 (1.10–2.32) NS
HDL-TG 0.34 (0.23–0.46) 0.31 (0.25–0.44) NS
LDL-TG 0.58 (0.42–0.64) 0.53 (0.41–0.69) NS
Chylomicron Chol 4.29 ± 5.43 2.17 ± 1.53 NS
Chylomicron TG 5.30 (2.73–11.52) 3.63 (2.30–6.40) NS
Apo A-I 1.04 ± 0.36 1.10 ± 0.30 NS
Apo B-100 0.91 ± 0.32 0.96 ± 0.27 NS
Apo CII 0.11 ± 0.05 0.13 ± 0.07 NSB
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Apo CIII 0.17 ± 0.07 0.20 ± 0.09 NS
Apo E 0.09 ± 0.04 0.11 ± 0.06 NS
ApoCIII/ApoCII 2.8 ± 4 1.7 ± 0.7 NS
Apo E Genotype NS
E3/E2 1 (4) 5 (16)
E3/E3 19 (79) 22 (73)
E3/E4 2 (8) 3 (10)
E2/E4 2 (8) 0
Apo A-V, allele S19W 8 (32) 7 (23) NS
LPLactivity
(mU/ml)
69 ± 44 92 ± 44 0.057
HL-activity
(mU/ml)
164 ± 94 194 ± 84 NS
Posth-LPLmass
(ng/ml)
312 ± 192 411 ± 195 0.06
Preh-LPLmass
(ng/ml)
18 ± 11 22 ± 14 NS
Data shown as mean ± SD unless Tg shown as median (IQ range). Units in SI. Note: Chylomicrons were found only in 12 subjects in the group HP and in 21 of the group HTG. Apo E and apo 
AV genotypes mean number (%).
Table 2: Serum lipids, lipoproteins, apolipoproteins and LPL mass and LPL and HL activities in postheparin and preheparin plasma samples (Continued)BMC Gastroenterology 2009, 9:46 http://www.biomedcentral.com/1471-230X/9/46
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over, among 129 patients with severe hypertriglyceridae-
mia referred to an Endocrinological Department for
evaluation, including 26 with acute pancreatitis, no one
was found to have LPL deficiency [9].
Our patients with hypertriglyceridaemic pancreatitis due
to LPL deficiency were clinically different from the those
with preserved LPL mass and activity, which explain their
greater frequency of episodes of recurrent pancreatitis, the
onset before adolescence, and the lower weight and body
mass index than the patients with hypertriglyceridaemic
pancreatitis and preserved LPL mass and activity. Analyti-
cally, besides the greater presence and levels of chylomi-
crons, the patients with a deficit had lower levels of LDL,
HDL, apo B-100 and apo A-1. Moreover, the patients with
hypertriglyceridaemic pancreatitis without LPL deficiency
were more likely to have associations with important
environmental factors, such as diabetes, obesity and alco-
hol consumption. The family association in some of these
patients, the lipoprotein profile with marked hyperchy-
lomicronaemia and the onset in childhood, all suggest a
diagnosis of familial LPL deficiency, although a definitive
diagnosis would require sequencing of the LPL gene or by
measuring postheparin plasma LPL activity.
Our study found no differential clinical or analytical traits
between the groups with hypertriglyceridaemic pancreati-
tis without LPL deficiency and the group of patients with
severe hypertriglyceridaemia that could be used for iden-
tification of patients with hypertriglyceridaemia who
might be predisposed to a pancreatic event. Notably, and
as opposed to what might be expected [27], the amount of
triglycerides and cholesterol in the chylomicrons did not
differ between the two groups either.
The patients were analysed during the stable phase of their
hyperlipidaemia, after several weeks or months of treat-
ment and at least several months since their last episode
of hypertriglyceridaemic pancreatitis. It is thus more than
likely that if the group with hypertriglyceridaemic pancre-
atitis been studied during the acute phase of the disease
and, not whilst they were stable, we would have obtained
greater information on those environmental factors that
could have triggered the disease, for example dietary
transgression such as a high consumption of fatty food or
alcohol, cessation of treatment or severe lack of diabetic
Post-heparin LPL activity in both groups, identifiying 5 indi- viduals with no activity Figure 2
Post-heparin LPL activity in both groups, identifiying 
5 individuals with no activity.
Table 3: clinical data of patients with LPL deficiency
HPND
N = 20
HTG
N = 30
HPD
N = 5
P
Age 47 ± 8 47 ± 7 23 ± 6 <0.001*
Age first onset AP 40 ± 11 - 6 ± 6 <0.001**
Episode AP number 1.75 ± 0.85 - 2.5 ± 0.6 NS
Sex (Male) 19 (95%) 27 (90%) 3 (60)% NS
Smokers 15 (75%) 19 (63%) - 0.006*
HLP AF 10 (50%) 12 (40%) 4 (80%) NS
Fibrates 13 (68%) 18 (58%) - NS
BMI 27.4 ± 3.6 29.7 ± 4.8 21.3 ± 1.6 0.01
HPD: patients with LPL deficiency.
*Differences between HPD and the others groups.
**: Differences between HPND and HPD.BMC Gastroenterology 2009, 9:46 http://www.biomedcentral.com/1471-230X/9/46
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Table 4: Serum lipids, lipoproteins and apolipoproteins in the three groups
HPND (N = 20) HTG (N = 30) HPD (N = 5) P
TC 6.36 ± 2.53 6.75 ± 1.58 8.66 ± 6.86 NS
TG 2.67 (1.85–5.00) 4.81 (2.57–7.83) 13.32 (7.69–29.77) 0.006*
VLDL-Chol 0.78 ± 0.41 0.91 ± 0.49 0.98 ± 0.59 NS
HDL-Chol 1.01 ± 0.47 0.91 ± 0.39 0.39 ± 0.13 0.01*
LDL-Chol 3.21 ± 1.40 3.39 ± 1.32 1.45 ± 1.27 0.01 *
VLDL-TG 1.27 (1.02–1.81) 1.39 (1.07–2.49) 1.94 (1.45–3.22) NS
HDL-TG 0.35 (0.28–0.46) 0.32 (0.25–0.46) 0.21 (0.14–0.44) NS
LDL-TG 0.56 (0.39–0.64) 0.53 (0.43–0.69) 0.59 (0.46–1.00) NS
Chylo-Chol 2.95 ± 3.34 2.22 ± 1.58 5.90 ± 7.55 NS
Chylo-TG 3.31 (2.52–7.40) 3.48 (2.21–6.60) 8.49 (5.2–23.81) 0.02**
Apo A-I 1.14 ± 0.29 1.11 ± 0.28 0.54 ± 0.17 <0.001 *
Apo B-100 0.98 ± 0.27 0.98 ± 0.25 0.56 ± 0.37 0.007 *
Apo CII 0.11 ± 0.06 0.13 ± 0.07 0.09 ± 0.05 NS
Apo CIII 0.17 ± 0.07 0.20 ± 0.09 0.19 ± 0.05 NS
Apo E 0.07 ± 0.04 0.11 ± 0.06 0.14 ± 0.03 0.005 *
CIII/CII 2 ± 3 1.7 ± 0.7 5 ± 7 NS
LPLactivity
(mU/ml)
82 ± 34 95 ± 41 0.4 ± 0.5 <0.001 *
HL-activity
(mU/ml)
179 ± 95 195 ± 86 107 ± 47 NS
Posth-LPLmass
(ng/ml)
365 ± 164 422 ± 190 58 ± 27 <0.001*
Preh-LPLmass
(ng/ml)
19 ± 10 22 ± 14 17 ± 12 NS
Data are shown as mean ± SD unless Tg shown as median (IQ range). HPD: patient with LPL deficiency. HPND: HP without LPL deficiency. TC: 
total cholesterol. TG: triglyceride. *: Differences between HPD and the others groups.** Differences between HPD and HTG group.BMC Gastroenterology 2009, 9:46 http://www.biomedcentral.com/1471-230X/9/46
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control. By the contrary, the acute phase of pancreatitis is
not the best clinical scenario to measure LPL activity
(pain, nasogastric tube, prophilactic heparin, inflamma-
tory state...).
Interaction of environmental factors with certain genetic
polymorphisms may also have triggered the onset of
hypertriglyceridaemic pancreatitis. The presence of the ε2
or ε4 allele in the apolipoprotein E gene has been associ-
ated with severe hypertriglyceridaemia [30], hypertriglyc-
eridaemic pancreatitis during pregnancy [11] and higher
postprandial levels of hyperlipidaemia [31]. Nevertheless,
our groups did not differ in the frequency of the non apo
E3/E3 genotypes. Certain polymorphisms in the apo A-V
gene have been associated with triglyceride levels in a
healthy population [32] and in persons with severe hyper-
triglyceridaemia [33,34] Indeed, severe chylomicronae-
mia with repeated hypertriglyceridaemic pancreatitis has
been reported in two persons with apo A-V deficit [35,36]
One mechanism proposed is that apo A-V lowers triglyc-
eride concentrations by guiding VLDL and chylomicrons
to proteoglycan-bound LPL for lipolysis [37] or simply
acting as a cofactor of the enzyme. In a group of persons
with hypertriglyceridaemia (triglycerides >3.80 mmol/L),
the prevalence of the rare allele S19W of apolipoprotein
A-V was found to be 19%, whereas it was only present in
4% of the control subjects [38]. The frequency of this rare
allele in our patients was spread unequally; it was absent
in the patients with LPL deficiency but was more common
in the patients with HPND than in the controls with
hypertriglyceridaemia, and may perhaps have contributed
to a greater predisposition in the former for the develop-
ment of pancreatitis due to the chylomicrons. Unfortu-
nately, our study was underpowered to reach any
conclusion.
Some limitations, however, should be taken into account
interpreting our data. Patients were seen several months
after the discharge of the bout of HP; second, many of
them have been treated with fibrates, which not only
modify lipids but also increase the LPL activity.
Conclusion
We found that a primary defect in the catabolism of TG-
rich lipoproteins was rare in patients who had survived a
bout of hypertriglyceridaemic pancreatitis. Quantification
of the LPL mass and activity should therefore be reserved
for patients with a normal body mass index and recurrent
acute pancreatitis that started in childhood or adoles-
cence. None of the known factors, such as the presence
and amount of fasting chylomicrons, the coexistence of
accompanying disease such as obesity or diabetes, or the
consumption of alcohol outside the acute phase, enabled
the hypertriglyceridaemic patients to be differentiated
from those with hypertriglyceridaemia who had devel-
oped hypertriglyceridaemic pancreatitis. Nevertheless,
certain genetic factors, such as the 19W variant of apo A-V
gene or other factors not studied here may predispose
patients with hypertriglyceridaemia to manage postpran-
dial fat worse and thereby make them more vulnerable to
hypertriglyceridaemic pancreatitis. Further studies along
similar lines and with a greater number of patients are
required to confirm these findings.
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